AU2001275269A1 - Liposomal benzoquinazoline thymidylate synthase inhibitor formulations - Google Patents

Description

LIPOSOMAL BENZOQUINAZOLINE THYMIDYLATE SYNTHASE INHIBITOR FORMULATIONS

Field of the Invention

This invention relates to liposomal formulations containing benzoquinazoline thymidylate synthase inhibitors. Further, this invention relates to methods of manufacturing and of using such formulations.

Background of the Invention

Liposomes are microscopic vesicles made, in part, from phospholipids which form closed, fluid-filled spheres when dispersed with water. A class of compounds, known as benzoquinazoline thymidylate synthase inhibitors, are known to have antitumor activity (U.S. 5,663,377). Described herein are liposomal formulations containing benzoquinazoline thymidylate synthase inhibitors.

Summary of the Invention

The present invention provides for liposomal formulations comprising at least one phosphatidylcholine, a cholesterol, and a benzoquinazoline thymidylate synthase inhibitor.

Brief Description of the Figures

Figure 1 depicts the log total plasma GWl 843 concentration versus time curves (Mean ± SD) following intravenous administration in male Sprague-Dawley rats of liposome encapsulated GWl 843 (NXl 843) or Free GWl 843. NXl 843 data fitted to a two phase exponential equation. Figure 2 depicts the tumor growth curve of HCT-8 treated tumors.

Figure 3 depicts the effects of NXl 843 and GWl 843 on body weight of nude mice.

Figure 4 depicts the dose-response effects of NXl 843 on tumor growth and body weight.

Figure 5 depicts the efficacy of NXl 843 in the molt4 leukemia model.

Detailed Description of the Invention

Formulations comprising benzoquinazoline thymidylate synthase inhibitors (BTSI) encapsulated in a liposome are provided as well as methods of their preparation. The formulations have pharmaceutical uses, including as anti-tumor or anti-viral agents, hi addition, the liposomes have improved pharmacokinetics and enhanced efficacy as anti-tumor agents as compared to the free drug. The formulations include liposomes comprised of at least one phosphatidylcholine, a cholesterol and a BTSI.

Benzoquinazoline thymidylate synthase inhibitors of the present invention (herein referred to as compound(s) of the invention) are described in United States Patent No. 5,663,337, September 2, 1997, which is incorporated by reference in its entirety, in particular, column 1, line 37 to column 6, line 45, inclusive, are incorporated by reference at this location.

Accordingly, the present invention provides compounds of the formula (1)

or a salt thereof, wherein the dotted line represents a single or double bond,

R¹ is - alkyl or amino optionally substituted by a Cι_₄ alkyl, C₁.₅ alkanoyl or benzyl group; R², R³, R⁴ and R⁵ are the same or different and each is selected from hydrogen, phenyl, halo, nitro, a group S(O)_n R⁸ wherein n is the integer 0, 1 or 2 and R⁸ is halo or is C₁-₄ alkyl or a group NR⁹ R¹⁰ wherein R⁹ and R¹⁰ are both hydrogen,

a group NR¹¹ R¹² wherein R¹¹ and R¹² are the same or different and each is hydrogen or Cι- alkyl,

a group OR¹³ wherein R¹³ is hydrogen or C₁-₄ alkyl optionally substituted by halo; a Cι- aliphatic group optionally substituted by a group OR¹⁴ or NR¹⁴ R¹⁵ wherein R¹⁴ and R¹⁵ are the same or different and each is hydrogen or Cι- alkyl;

or two of R² to R⁵ are linked together to form a benzo group, or one of R² to R⁵ is a group -X-Y-R¹⁶ wherein X is CH₂, NR¹⁷, CO or S(O)_m and m is 0, 1 or 2 and R¹⁷ is hydrogen or a Cι- aliphatic group and Y is CH₂, NR¹⁷ , O, or S(O)_m, wherein m' is 0,1 or 2 and R¹⁷ is hydrogen or a Cι-₄ aliphatic group provided that X and Y are only the same when each is CH₂, or -X-Y- is a group -O-, -NR¹⁷-, - CH=CH- or -N=N- wherein R¹⁷ is as hereinbefore defined, R¹⁶ is a C₁. aliphatic group or a 5- or 6- membered aromatic ring optionally substituted by a group R¹⁸ at a position at least one carbon atom removed from that linked to Y, the 5- or 6- membered ring being optionally further substituted by a halo atom; and R¹⁸ is halo, Cι.₄ alkoxy, nitro, nitrile, Cι-₄ alkyl optionally substituted by halo, halo or a group COR¹⁹ wherein R¹⁹ is hydroxy, Cι-₄ alkoxy or C^ alkyl optionally substituted by one or two carboxyl groups or -₁₂ esters thereof or R¹⁹ is a group NR²⁰R²¹ wherein R²⁰ and R²¹ are the same or different and each is hydrogen or Cι-₄ alkyl optionally substituted by hydroxy or R¹⁹ is an amino acid group or an ester thereof in which the first nitrogen atom of the amino acid group may be linked to the 5- or 6-membered aromatic ring to form a further 5- or 6- membered heterocyclic ring or R¹⁹ is an C₂.₃ alkylene group linked to the 5- or 6- membered aromatic ring to form a further 5- or 6- membered ring; R⁶ and R⁷ are the same or different and each is Cι-₄ alkyl optionally substituted by hydroxy or Ci- alkoxy or together form a benzo group;

provided that at least one of R² to R⁷ is other than hydrogen and that R⁴ is not methoxy when R¹ is hydroxy or methyl.

By the term halo is meant fluoro, bromo, chloro and iodo.

By the term Cι_₄ aliphatic group is meant a C₁-₄ alkyl, alkenyl, or alkynyl group.

By the term amino acid group is meant naturally occurring amino acids.

Preferred amino acid groups include glycine, glutamic acid and polyglutamic and groups.

When the amino acid group is linked to the 5- or 6- membered aromatic ring, this is via a carbon atom of the aromatic ring adjacent to carbon to which COR¹⁹ is attached.

Preferably the dotted line is a double bond.

Suitable substituents for the aromatic ring R¹⁶ include halo, Cι- alkyl and C₁- alkoxy each optionally substituted by one to five halo atoms. Most suitably there are one or two substituents selected from fluoro, chloro, methyl, trifluoromethyl and methoxy, and preferably fluoro, or no substituents on the aromatic ring, hi one preferred embodiment, -X-Y-R¹⁶ is a group

wherein R¹⁸ is as hereinbefore defined and preferably a group COR¹⁹ as hereinbefore defined and R ,2 is hydrogen or fluoro.

hi a further preferred embodiment X-Y-R¹⁶ is a group

wherein H₂NR^19a is a glutamic or polyglutamic acid group and Z is CH₂, S or O. Suitably, R¹ is an amino group optionally substituted by one or two methyl or ethyl groups or R¹ is a methyl or ethyl group. Preferably R¹ is an amino or methyl group.

Suitably, at most only three, and preferably at most only two, of R² to R⁵ are other than hydrogen and each is independently selected from hydrogen, halo, hydroxy, nitro, Cι-₃ alkyl optionally substituted by hydroxy or Cι-₂ alkoxy, Cι-₃ alkoxy, amino optionally substituted by one or two methyl or ethyl groups, or a group S(O)n R²³ wherein n is 0, 1 or 2 and R²³ is a Cι- alkyl group or an amino group optionally substituted by one or two methyl or ethyl groups, or one of R² to R⁵ is a group -X-Y-R²⁴ where R²⁴ is a group

wherein R¹⁸, R^19a, R²² and Z are as hereinbefore defined, hi one preferred embodiment R¹⁸ is nitro or a group

CONHCHCO K

(CH_>)₂CO NHCHCOOR²⁶ 2 (CH₂)₂CO OR' 7 wherein R²⁵, R²⁶ and R²⁷ are the same or different and each is hydrogen or a ^ alkyl group and t is an integer from 0 to 6. Preferably R²⁵, R²⁶ and R²⁷ are hydrogen and t is 0. Preferably Z is CH₂ or S.

Preferably one of R to R is a group -X-Y-R 24 as hereinbefore defined. Preferably R is a group -X-Y-R 24

Suitably R⁶ and R⁷ are the same or different and each is hydrogen, methyl, ethyl or methyl substituted by bromo, hydroxy or methoxy. Preferably R⁷ is hydrogen and R⁶ is methyl.

Preferably -X-Y- is a group -SO₂NR¹⁷- or CH₂NR¹⁷ wherein R¹⁷ is as hereinbefore defined.

Suitably R¹⁷ is hydrogen or a Cι- alkyl or alkenyl group and preferably R¹⁷ is hydrogen or methyl.

One group of compounds of the present invention is that of the formula (la)

or a salt thereof, wherein the dotted line represents a single or double bond, R^la is Cι- alkyl or amino optionally substituted by a Cι- alkyl, Cι-₅ alkanoyl or benzyl group; R^2a, R^3a, R^4a and R^5a are the same or different and each is selected from hydrogen, halo, nitro, a group S(O)_nR^8a wherein n is the integer 0, 1 or 2 and R^8a is halo or is a Cι- alkyl or amino group; a group NR^llaR¹² wherein R^lla and R^12a are the same or different and each is hydrogen or Cι- alkyl, a group OR^13a wherein R^13a is hydrogen or - alkyl optionally substituted by halo, a Cι-₄ aliphatic group optionally substituted by a group OR^14a or NR^14aR^15a wherein R^14a and R^15a are the same or different and each is hydrogen or -₄ alkyl, or one of R^2a to R^5a is a group -X-Y-R^16a wherein X is CH₂, NR^17a, CO or S(O)_m and m is 0, 1 or 2 and R^17a is hydrogen or a Cχ.₄ ahphatic group and Y is CH₂, NR₁₇>_a, O, or S(O)_m, wherein m' is 0, 1 or 2 and R^{17 a} is hydrogen or a -₄ aliphatic group provided that X and Y are only the same when each is CH₂, or -X-Y- is a group -NR^17a, -CH=CN- or -N=N- wherein R^17a as hereinbefore defined, R¹⁶ is a Cι- ahphatic group or an optionally substituted 5- or 6- membered aromatic ring substituted by a group R^18a at a position at least one carbon atom removed from that linked to Y and R^18a is nitro, nitrile, Cι- alkyl optionally substituted by halo, halo or a group COR^19a wherein R^19a is C₁-₆ alkyl optionally substituted by one or two carboxyl groups or Cι- alkoxy, a group CONR^20aR^21a wherein R^20a and R^21a are the same or different and each is hydrogen or Cι- alkyl or R^19a is a glutamic or polyglutamic acid group or an ester thereof in which the first nitrogen atom of the glutamic or polyglutamic acid group may be linked to the 5- or 6-membered aromatic ring to form a further 5- or 6- membered heterocychc ring; R^6a and R^7a are the same or different and each is Cι-₄ alkyl optionally substituted by hydroxy or Cι-₄ alkoxy or together form a benzo group, provided that at least one of R^2a to R^7a is other than hydrogen and that R^4a is not methoxy when R^la is hydroxy or methyl.

A further group of compounds of the present invention is that of the formula (H)

or a salt thereof, wherein R¹, R⁶, R⁷ and the dotted line are as hereinbefore defined and R²⁸ to R³¹ are the same or different and each is selected from hydrogen, halo, nitro, a group S(O)_nR⁸, a group NR^πR¹², a group OR¹³, or a Cι-₄ ahphatic group optionally substituted by a group OR¹⁴ or NR¹⁴R¹⁵ wherein R⁸, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ are as hereinbefore defined, provided that R²⁸ to R³¹ are not all hydrogen and that

R >30 is not methoxy wherein R is hydroxy or methyl.

A preferred group of compounds of the present invention is that of the formula (ID):

or a salt thereof, wherein R¹, R⁶ and R⁷ are as hereinbefore defined and R³² to R³⁵ are the same or different and one is a group X-Y-R¹⁶ and the others are the same or different and each is selected from hydrogen, halo, nitro, a group S(O)_nR⁸, a group NR^πR¹², a group OR¹³ or a Cι-₄ ahphatic group optionally substituted by a group OR¹⁴ or NR¹⁴R¹⁵, wherein X, Y, R⁸, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are as hereinbefore defined.

A further preferred group of compounds of the present invention is that of the formula (IV):

wherein R¹, R⁶ R⁷ and R³² to R³⁵ are as hereinbefore defined.

Preferably R ,33 is a group X-Y-R 16 as hereinbefore defined Preferred compounds of the formula (I) include:

3-Amino-9-bromobenzo[fjquinazohn-l(2H)-one 3-Amino-9-ethynylbenzo[f]quinazoHn-l(2H)-one

N-(4-((3-Amino-l,2,5,6-tetrahydro-l-oxobenzo[f]quinazohn-9- yl)sulfonanήdo)benzoyl)-L-glutamic acid

N-(4-((l,2,5,6-tetrahydro-3-methyl-l-oxobenzo[f]quinazohn-9-yl)- sulfonaπύdo)benzoyl)-L-glutarnic acid N-(4-((l,2-Dihydro-3-memyl-l-oxobenzo[f]quinazohn-9- yl)sulfonamido)benzoyl)-

L-glutamic acid

N-(4-(((l,2-Dihydro-3-methyl-l-oxobenzo[f]quinazohn-9- yl)methyl) amino)-2- fluorobenzoyl)-L-glutamic acid

N-(4(((l,2-Dihydro-3-methyl-l-oxobenzo[fJquinazohn-9-yl)methyl) arnino)benzoyl)- L-glumatic acid

(S)-2-(5-(((l,2-Dihydro-3-methyl-l-oxobenzo[fJquinazohn-9- yl)methyl)amino-l- oxo-2-isoindohnyl)glutaric acid

9-((4-Acetylanihno)methyl)-3-methylbenzo[fjquinazohn-l(2H)-one

3-Methyl090 ((4-nitroanihno)methyl)benzo[f]quinazohn-l (2H)-one N-(4-(((3-Amino-l,2-dihydro-l-oxobenzo[fjquinazohn-9-yl)methyl) amino)benzoyl)-

L-glutamic acid

3-Amino-9-((4-nitroanihno)methyl)benzo[f]quinazohn-l(2H)-one

9-((4- Acetylanihno)methyl)-3 -aminobenzo [f] quinazolin- 1 (2H)-one

(RS)-2-(2-(4-(((l,2-Dihydro-3-methyl-l-oxobenzo[fJquinazohn-9- yl)methyl)amino)phenyl)-2-oxoethyl)glutaric acid

Ethyl-4-(4-(((l,2-dihydro-3-methyl-l-oxobenzo[f]quinazohn-9-yl) methyl)amino)phenyl)-4-oxobutyrate

4-(4-(((l ,2-Dihydro-3-methyl-l-oxobenzo[fjquinazohn-9- yl)methyl) amino)phenyl)-

4-oxobutyric acid N-(4-(((l,2-Dihydro-3-methyl-l-oxobenzo[fJquinazohn-9- yl)methyl) amino)-2- fluorobenzoyl)glycine

Ethyl N-(4-(((l,2-Dihydro-3-methyl-l-oxobenzo[f]quinazohn-9-yl) methyl)arnino)-2- fluorobenzoyl)glycinate

Certain compounds of the formula (I) contain asymmetric carbon atoms and are, therefore, capable of existing as optical isomers. The individual isomers and mixtures of these are included within the scope of the present invention.

Salts of the compounds of the present invention may comprise acid addition salts derived from an amino group or anionic species derived from a compound of formula (1), for example when this is substituted by a carboxy group, and a cation. In both types of salts, the therapeutic activity resides in the moiety derived from the compound of the invention as defined herein and the identity of the other component is of less importance although for therapeutic and prophylactic purposes it is, preferably, pharmaceutically acceptable to the patient. Examples of pharmaceutically acceptable acid addition salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic and methanesulphonic and arylsulphonic, for example p-toluenesulphonic, acids. Examples of salts comprising an anionic species derived from a compound of formula (I) and a cation include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth salts, such as magnesium and calcium salts, and salts formed with organic bases, for example, amino salts derived from mono-, di- or tri-(lower alkyl) or (lower alkanol)amines, such as triethanolamine and diethylamino- ethylamine, and salts with heterocychc amines such as piperidine, pyridine, piperazine and morpholine. The pharmaceutically acceptable salts together with the salts which are not thus acceptable have utihty in the isolation and/or the purification of the compounds of the invention, and the pharmaceutically unacceptable salts are also useful in being convertible to the pharmaceutically acceptable salts by techniques well known in the art.

Esters of compounds of the formula (I), formed from compounds of the formula (I) which contain a carboxy group are often useful intermediates in the preparation of the parent acid.

One particularly preferred compound of the present invention is a compound, GWl 843 (also called GW1843U89 or 1843U89 herein), of the formula:

GW1843

As used herein, the liposomal formulations of GWl 843 are referred to as NXl 843.

As used herein, the term "hposome" refers to unilamellar vesicles or multilamellar vesicles such as are described in U.S. Patent No. 4,753,788, the contents of which are incorporated herein by reference. "Unilamellar liposomes," also referred to as "single lamellar vesicles," are spherical vesicles comprised of one hpid bilayer membrane which defines a single closed aqueous compartment. The bilayer membrane is composed of two layers of hpids; an inner layer and an outer layer (leaflet). The outer layer of the hpid molecules are oriented with their hydrophilic head portions toward the external aqueous environment and their hydrophobic tails pointed downward toward the interior of the hposome. The inner layer of the hpid lays directly beneath the outer layer, the hpids are oriented with their heads facing the aqueous interior of the hposome and their tails toward the tails of the outer layer of hpid.

"Multilamellar liposomes," also referred to as "multilamellar vesicles" or "multiple lamellar vesicles," are composed of more than one hpid bilayer membrane, which membranes define more than one closed aqueous compartment. The membranes are concentrically arranged so that the different membranes are separated by aqueous compartments, much like an onion. The terms "encapsulation" and "entrapped," as used herein, refer to the incorporation or association of the BTSI in or with a hposome . BTSI may be present in the interior aqueous space of the hposome, in the inner or outer leaflet of the membrane bilayer, partially buried in the outer leaflet of the bilayer and partially external to the hposome, or associated with the surface of the hposome, e.g., by electrostatic interactions, or a combination of these.

The term "excipient," as used herein, refers to a substance or substances that can facihtate the stability of drug product, including, but not hmited to, the stabihty of pH, the stabihty of colloidal properties of hposome, and chemical stabihty of drug substance and phosphohpids. Examples of excipients include, but are not hmited to, the acid, sodium or ammonium forms of monovalent anions such as chloride, acetate, lactobionate and formate; divalent anions such as aspartate, succinate and sulfate; and trivalent ions such as citrate and phosphate.

"Phosphohpid" refers to any one phosphohpid or combination of phosphohpids capable of forming hposomes. Phosphatidylchohnes (PC), including those obtained from egg, soy beans or other plant sources or those that are partially or wholly synthetic, or of variable hpid chain length and unsaturation are suitable for use in the present invention. Synthetic, semisynthetic and natural product phosphatidylchohnes including, but not hmited to, distearoylphosphatidylcholine (DSPC), hydrogenated soy phosphatidylchohne (HSPC), soy phosphatidylcholine (soy PC), egg phosphatidylchohne (egg PC), dioleoylphosphatidylchohne (DOPC), hydrogenated egg phosphatidylchohne (HEPC), dielaidoylphosphatidylcholine (DEPC), dipalmitoylphosphatidylchohne (DPPC) and dimyristoylphosphatidylcholine (DMPC) are suitable phosphatidylchohnes for use in this invention. All of these phosphohpids are commercially available. Preferred PCs are HSPC and DSPC; the most preferred is HSPC.

Further, phosphatidylglycerols (PG) and phosphatic acid (PA) are also suitable phosphohpids for use in the present invention and include, but are not hmited to, dimyristoylphosphatidylglycerol (DMPG), dilaurylphosphatidylglycerol (DLPG), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylglycerol (DSPG) dimyristoylphosphatidic acid (DMPA), distearoylphosphatidic acid (DSPA), dilaurylphosphatidic acid (DLPA), and dipahnitoylphosphatidic acid (DPP A). Distearoylphosphatidylglycerol (DSPG) is the preferred negatively charged hpid when used in formulations. When a negatively charged hpid , such as DSPG, is included in the formulation, it is preferred that it is in a molar amount of less than 20% of the total hpid, and more preferably less than 5%. Other suitable phosphohpids include phosphatidylethanolamines, phosphatidyhnositols, and phosphatidic acids containing lauric, myristic, stearoyl, and palmitic acid chains. Further, incorporation of polyethylene glycol (PEG) containing phosphohpids is also contemplated by the present invention. The term "parenteral" as used herein refers to intravenous (IV), intramuscular

( ), subcutaneous (SubQ) or intraperitoneal (IP) administration.

Any phospholipid:BTSI ratio that is efficacious is contemplated by this invention. Preferred phospholipid:BTSI molar ratios are 5:1 to 75:1, more preferably 8 : 1 to 20: 1. Preferred hposomal formulations include phospholipid holesterol molar ratios over the range of 5: 1 to 2: 1.5. The most preferred hposomal formulation is 2: 1 PC holesterol. In the preferred embodiment, the hposomes are unilamellar vesicles having a median size less than 100 nm, wherein the phosphohpid is hydrogenated soy phosphatidylchohne (HSPC) and includes cholesterol in a 2:1 molar ratio and the BTSI is GWl 843.

GeneraUy, the process of preparing the formulation embodied in the present invention is initiated with the preparation of a solution from which the hposomes are formed. This is done, for example, by weighing out a quantity of a phosphatidylchohne and cholesterol and dissolving them in an organic solvent, preferably chloroform, or a mixture of solvents, preferably chloroform and methanol. The solution is evaporated to form a sohd hpid phase such as a film or a powder, for example, with a rotary evaporator, spray dryer or other means. The preferred drying method is using a spray dryer. The film or powder is then hydrated with an aqueous solution containing the active drug, and with or without excipients to form a hposome dispersion. It is preferred that no excipient is used other than acid or base used for pH adjustment of the drug solution. The hpid film or powder dispersed in the drag solution is heated to a temperature from about 25°C to about 70°C depending on the phosphohpids used.

Multilamellar hposomes are formed by agitation of the dispersion, preferably through shaking or mixing. Unilamellar vesicles are formed by the application of energy, such as a shearing force, or cavitation, to an aqueous dispersion of the hpid sohd phase, e.g., by sonication or the use of a microfluidizing apparatus, or an extrusion apparatus, or a homogenizer or a French press. Liposomes can also be prepared using either injection, freezing and thawing, dialyzing away a detergent solution from hpids, or other known methods used to prepare hposomes. The size of the hposomes can be controUed using a variety of known techniques including the duration of the application of energy. Preferably, a homogenizing apparatus is employed to form unilamellar vesicles having diameters of less than 100 nanometers at a pressure of 3,000 to 20,000 psi, preferably 10,000 to 14,000 psi and a temperature of about the aggregate transition temperature of the hpids, preferably above 55°C for a HSPGChol formulation.

Unentrapped excipient and/or drug is removed from the hposome dispersion by buffer exchange to aqueous solution using either dialysis, size exclusion column chromatography (Sephadex G-50 resin) or ultrafiltration (also known as cross filtration) (50,000 - 300,000 molecular weight cut off). The therapeutic use of hposomes can include the delivery of drugs which are normally toxic in the free form. In the hposomal form, the toxic drug may be directed away from the sensitive tissue where toxicity can result and targeted to selected areas where they can exert their therapeutic effects. Liposomes can also be used therapeuticaUy to release drugs slowly, over a prolonged period of time, thereby reducing the frequency of drug administration through an enhanced pharmacokinetic profile, h addition, hposomes can provide a method for forming an aqueous dispersion of hydrophobic drags for intravenous delivery.

The route of delivery of hposomes can also affect their distribution in the body. Passive delivery of hposomes involves the use of various routes of administration e.g., parenterally, although other effective administration forms, such as inrraarticular injection, inhalant mists, orally active formulations, transdermal iotophoresis or suppositories are also envisioned. Each route produces differences in localization of the hposomes.

The invention also provides a method of inhibiting the growth of tumors, both drag resistant and drug sensitive, by delivering a therapeutic or effective amount of hposomal BTSI to a tumor, preferably in a mammal. The optimal quantity and spacing of individual dosages of the formulations herein will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It wiU also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

Inhibition of the growth of tumors associated with all cancers is contemplated by this invention, including multiple drag resistant cancer. Cancers for which the described hposomal formulations may be particularly useful in inhibiting are colorectal, ovarian, lung, breast, head and neck, prostate, uteran, glioblastoma, and sarcomas, hi addition, it is contemplated that the formulations described and claimed herein can be used in combination with other anticancer treatments, including, but not hmited to, 1) taxol (pachtaxel) and platinum complexes for treating ovarian cancer; 2) 5FU and leucovorin or levamisole for treating colorectal cancer; 3) cisplatin and etoposide for treating lung, 4) topo I inhibitors such as topotecan, irinotecan, and NX211, and 5) anthracychnes, such as doxorabicin or doxil.

This invention will be more fully understood by reference to the following examples, which are intended to be illustrative of the invention, and not hmiting thereof. Example 1 describes the hposomal formulations of GWl 843. Example 2 describes single dose pharmacokinetics of four hposomal formulations. Example 3 describes the comparison of plasma pharmacokinetic parameters between free GWl 843 and a hposomal formulation of GWl 843. Example 4 describes the comparison of two independent lots of a single NXl 843 formulation. Example 5 describes the comparison of different hposome formulations and determination of the effect of animal weight on plasma pharmacokinetics. Example 6 describes plasma pharmacokinetics following a single intravenous bolus administration. Example 7 describes preclinical studies on the TS inhibitor GWl 843 and the hposomal formulation NX 1843.

Example 1

Liposomal Formulations of GW1843

Phosphohpids and cholesterol used herein were obtained as dry powders from Avanti Polar Lipids, Nippon Fine Chemical, Lipoid, or Sygena and were used without further purification. All other chemicals were reagent grade and were used without further purification.

The hposome preparation of GWl 843 consists of the encapsulation of the drag in the internal space of hposomes. First, hpid films or spray dried powders containing hydrogenated soy phosphatidylchohne and cholesterol were prepared. HSPC:Chol at 2:1 molar ratio was prepared using spray dry method. The hpids were dissolved in chloroform up to 20% w/w. The hpid components in the organic solvent solution was then dried down to a powder using nitrogen gas between 72-78°C. HSPC:Chol at 4:1 molar ratio was prepared using the film method. To prepare hpid films, a solvent mixture (273 mg/ml) of chloroform and methanol (1:1 volume ratio) was used to dissolve the hpid components. The solvent was then removed by running nitrogen through the solution while the solution is heated in a 65°C temperature bath. Each hpid powder or film was hydrated at hpid concentrations in the final product up to 100-200 mg/ml in an aqueous solution containing the active drag at concentrations of 20-225 mg/ml, with or without the presence of phosphate buffer (used to buffer solution pH), in the pH range of 7-9. Samples NA-1022-63A, NA-1022-59A, GC- 1007-27, and GC-1020-36 were prepared using 150 mM phosphate buffer. The other samples were prepared without phosphate buffer. (AT-1084-95B) was incubated with acetic acid at above the phase transition temperature of the phosphohpid, which may have resulted in the observed low pH of the final product (Table 1A)„ HSPC:Cholesterol molar ratio were between 4:1 to 2:1. Small unilamellar hposomes (<100 nm, median diameter using the MicroTrac Ultrafme Particle Analyzer) were then formed from these mixtures at temperatures above the hpid phase transitions (-55 °C) using probe sonication. Drug and/or excipients that were not entrapped in the aqueous core of the hposomes were removed from the hposome dispersion generally by buffer exchange to water or 9% sucrose using size exclusion column chromatography (Sephadex G-50 resin). For preparations that use water as eluent, sucrose was added subsequent to the separation of unentrapped drag and/or excipients from hposomes.

Samples were filtered at ambient temperature through a 0.22 micron filter composed of either cellulose acetate or polyether sulfone. Results of characterization are shown below in Table 1A. Other formulations were prepared using phosphohpids other than HSPC

(Table IB). A negatively charged phosphatidylchohne, DSPG, was also used in one formulation (Table IB). Lipid films were prepared as described above for AL1230- 058, AL1230-052, AL1230-048, and AL1230-055 with 100 mg/ml chloroform and methanol. Spray dried powders were prepared as described above for AL1230-041. Each hpid film or powder was hydrated in a drag solution of lOOmg/mL, pH 7.5. After mixing, the hydrated hpid was homogenized using a homogenizer (Panda made by Niro) at ~65°C and -13,000 psi pressure to form small unilamellar vesicles. After homogenization, the hposomes were cross-filtered against water for injection to remove the unencapsulated drag. At the end of cross-filtration, sucrose was added to the bulk to a concentration of approximately 9%. The hposome solutions were filtered through 0.2 μm Polyether sulfone (PES) filter. Test results of these formulations are shown in Table IB.

Additional formulations were prepared using different excipients, such as sucrose, phosphate, citrate, and succinate, for the HSPC:Chol (molar ratio 2:1) formulation. The spray dried powder of HSPCChol (2: 1) molar ratio) was hydrated in a drag solution of 100 mg/ml, pH 7.5. After mixing, the hydrated hpid was homogenized using a homogenizer (Panda made by Niro) at 65 °C and 13,000 psi pressure to form small unilamellar vesicles. After homogenization, the hposomes were cross-filtered against water for injection to remove the unencapsulated drag. At the end of cross-filtration, sucrose was added to the bulk to a concentration of approximately 9%. Additional buffer excipients were added (Table 1C) to a desired concentration and solution pH was adjusted. The hposome solutions were filtered through 0.2 μm Polyether sulfone (PES) filter. Some test results of these formulations are presented in Table IC. The stabihty data of the formulations are listed in Table ID. The formulations are stable over at least one month at 2-8°C. Example 2

Single Dose Pharmacokinetics of Four Liposomal Formulations

The plasma pharmacokinetics of free GWl 843 and 4 different hposome formulations (see Table 1A; GC-1007-27, GC-1020-36, NA-1022-63A, and NA- 1022-59 A) of GWl 843 in rats following a single intravenous bolus administration are compared. The hposome formulations differed by the pH utihzed to load the hposome. NXl 843 lot nos. GC-1007-27, GC-1020-36, NA-1022-63A, and NA- 1022-59 A were loaded at pH 7.0, 7.4, 7.3 and 7.5, respectively.

Materials and Methods

A total of fifteen Sprague Dawley rats were used in the study. Each rat weighed approximately 250 grams. Three animals were assigned to each group (five groups in total). Individual animals were weighed and dosed at 1 mg/kg body weight by intravenous bolus administration into the tail vein while under isoflurene anesthesia. EDTA blood samples were taken at the time points shown in Table 2 while under isoflurene anesthesia and immediately processed into plasma. Plasma was stored at -20°C until analysis.

Plasma samples were prepared and analyzed for GWl 843 by the use of a non- vahdated HPLC assay. FoUowing methanol precipitation of plasma protein, the soluble GWl 843 was separated by C-18 reverse phase column chromatography. Separation was achieved by an isocratic method. Running buffer consisted of 80% acetonitrile and 20% 100 mM ammonium acetate pH = 5.3. Area under the peak versus concentration of GWl 843 was used to construct the standard curve. Pharmacokinetic parameters were determined by non-compartmental analysis

(WinNonhn version 1.5). Pharmacokinetic parameters were determined for each experimental group using the average concentration versus time values for each group. The following parameters were calculated: Maximum plasma concentration (Cmax); area under the plasma concentration versus time curve extrapolating to infinite time (AUCinf) or to last time point (AUClast); ehmation half-life

(Ehm.Tl/2); mean residence time (MRT) plasma clearance (Cl) and volume of distribution at steady state (Nss).

Results The plasma concentrations for each dose group are summarized in Table 2.

Calculated pharmacokinetic parameters are shown in Table 3.

Νoncompartmental Analysis

Νoncompartmental analysis makes no assumptions about the underlying pharmacokinetic model. Estimates for the maximum achieved concentrations

(Cmax) in the plasma ranged from 15.5 to 24.8 μg/mL for the hposomal formulations and 1.3 μg/mL for the free drag. The estimated ehmination half-hfe (Ehm.tl/2) of all four hposome formulations was significantly greater than for the free drag. The ehmination half-lives of the hposome formulations were all approximately 18.5 hours while the free drug displayed an ehmination half-hfe of approximately 0.5 hours. The area under the plasma concentration versus time curve (AUCinf) for the hposomal formulations ranged from 266,740 to 462,920 (h x ng/mL) compared to just 263 (h x ng/mL) for the free drag. This latter result is reflected in the plasma clearance, which ranged from 2.16 to 3.75 mlJh for the hposome formulations and was 3,805 lriL/h for the free drag. Finally, the volume of distribution at steady state (Nss) for the hposome formulations ranged from 2 to 3 times the expected plasma volume of the rat (31.2 mlJkg) (3) while the free drag had a volume of distribution 18 to 30-fold greater than the hposome formulations.

Example 3

Comparison of plasma pharmacokinetic parameters between free GW1843 and a liposomal formulation of GW1843

Materials and Methods GWl 843 (M.W. 500.51 g/mol) was obtained from Glaxo Wellcome, hie. and suspended as an aqueous. Briefly, 616.74 milligrams of GWl 843 was suspended in 1.4 mL 2 Ν ΝaOH. The solution was mixed until dissolved. To the dissolved solution 30 mL sahne was added. The pH was adjusted to 7.15 with 2 Ν HC1. Finally, the solution was brought to 46.545 mL with sahne. The nominal concentration was 13.25 mg/mL. UN absorption in 0.1 Ν sodium hydroxide at 266 nm, based on an extinction coefficient of 4.34 x 104 cm^"1 M^"1, determined the concentration. The concentration by UN spectroscopy was 13.97 mg/mL (5.4% difference from expected). The value determined by spectroscopy was utihzed for standards in the HPLC assay. ΝX1843 lot SMC-991-96 (see Table 1A) was used for making quality control solutions. Male Sprague-Dawley rats weighing 343.91 to 420.19 grams were used for the study. The in-hfe phase of the study was conducted in Boulder Colorado in accordance with the guidelines for animal welfare and care (NRC Pubhcation Guide for the Care and Use of Laboratory Animals, 1996). IACUC protocol number N98010. Animals were allowed free access to food and water before and during treatment.

Individual animals treated with NXl 843 were weighed and dosed at 1 mg/kg body weight by intravenous bolus administration into the tail vein while under isoflurane anesthesia. Serial EDTA-blood samples (0.5 mL) were obtained at 5, 15, 30 and 45 minutes, and 1, 1.5 and 2 hr post-dosing for the GWl 843 group while animals were under isoflurane anesthesia. For the NXl 843 group, serial EDTA-blood samples (0.5mL) were obtained at 10, 30 and 90 minutes and 4, 8, 24, 32, 48, 72 and 96 hours post-dosing. The EDTA-blood samples were immediately processed for plasma and plasma samples were stored at -20°C until analysis.

An isocratic reverse phase high performance hquid chromatographic (HPLC) procedure was used for rapid determination of the total GWl 843 concentration in rat EDTA-plasma. Following methanol precipitation of plasma protein (2 parts methanol to 1 part plasma), the protein was removed by centrifugation at 14,000 x g for 10 minutes. A ZORBAX Eclipse™ XBD-Cl 8 column (3mm x 15 cm) configured with a guard column was used to separate the soluble GWl 843 (injection volume 20 μL). The HPLC buffer consisted of 80% 100-mM ammonium acetate pH 5.3, and 20% acetonitrile and the flow rate was 0.4 mlJmin. The total ran time was seven minutes and GWl 843 was detected and quantified by ultraviolet absorbance at 264 nm. The standard curve consisted of free GWl 843 spiked rat EDTA-plasma while the quahty control samples consisted of NXl 843 spiked rat EDTA-plasma. The range of the standard curve was 0.1 to 30.0 μg/mL.

The pharmacokinetic parameters for total GWl 843 after i.v administration of GWl 843 or hposome encapsulated GWl 843 were assessed by a non-compartmental method using WinNonhn (version 1.5). The log/hnear trapazoidal rale was used. For non-compartmental analysis, all three time points were utihzed for the estimation the ehmination phase for free GWl 843 while the last 5 time points were utihzed to estimate the ehmination half-hfe of NXl 843. Cmax values were estimated by extrapolation to zero time. Pharmacokinetic parameters were determined for each animal in the study. From values obtained in each group the mean and SD of each parameter was determined. The parameters estimated included:

Cmax The maximum plasma concentration.

AUC(O-last) The area under the plasma concentration versus time curve up to the last time plasma time point measured.

ke The slope of the terminal ehmination phase, estimated by linear regression. ti/2 The half-hfe of the terminal ehmination phase (0.693/ke).

MRT(O-inf) Mean residence time extrapolated to infinity.

AUC(O-inf) The area under the concentration versus time curve extrapolated to infinity.

The observed clearance (CL) of GWl 843 following administration was calculated as: CL = Dose_iv /AUC

Comparison of treatment groups was performed by unpaired t-tests of data obtained in the same experiment. A p- value of <0.05 was considered significant. Tests were performed using GraphPad istat version 1.0 (GraphPad Software).

Results

Non-Compartmental Analysis of GW1843 and Liposome Encapsulated GW1843

(NX1843)

The total plasma concentrations for the GWl 843 dose group are summarized in Table 4 while the corresponding total plasma concentrations for the hposome encapsulated GWl 843 (NXl 843; SMC-991-96) dose group are summarized in Table 5. The estimated values of several calculated pharmacokinetic parameters for GWl 843 and NXl 843 are given in Table 6 and Table 7, respectively. Pharmacokinetic values for the GWl 843 dose group are based on a terminal half-hfe estimated by all three measured GWl 843 plasma concentrations. This probably results in an underestimate of the half-hfe and thus a slight underestimate of the AUC. However, such an approach is necessitated by the hmited data at this dose level.

Figure 1 shows the log concentration versus time curves for the two dose groups.

Estimates for the maximum achieved concentrations (Cmax) in the plasma of animals receiving NXl 843 ranged from 22.1 to 28.7 μg/mL of total GWl 843. These values were significantly greater than observed for free GWl 843 (Range 1.62 to 1.99 μg/mL). The estimated (mean ± SD) terminal half-hfe (Ehm.tl/2) of the hposome formulation was 16.6 ± 0.86 hours while the free drag displayed an ehmination half- hfe of 0.142 ± 0.007 hours. The area under the GWl 843 plasma concentration versus time curve [AUC(O-inf)] for the hposomal formulation was 524 ± 55.9 hr.μg/mL compared to just 0.27 ± 0.028 frr.μg/mL for the free drag. This latter result is reflected in the plasma clearance, which was 1.93 ± 0.206 mL/hr for the hposome formulation and was 3,740 ± 456 mlJhr for the free drug. Finally, the volume of distribution at steady state (Nss) for the hposome formulation was less than twice the expected plasma volume of the rat (31.2 mlJkg) (3) while the free drug had a volume of distribution on the order of 14.6-fold greater than the hposome formulation.

Liposome encapsulation of GWl 843 gave an approximately 1, 940-fold increase in total plasma exposure in comparison to the free drag. This value is similar to the values obtained in Example 2 where 1,000 to 1, 760-fold increases were observed. hi general, the pharmacokinetic parameters of ΝX1843 observed in this Example were similar to those observed in Example 2.

The average terminal half-hfe of 18.0 hours determined for the NXl 843 formulation in this example was not significantly different from any of the terminal half-lives (Range 17.7 to 20.2 hours) obtained for the four NXl 843 formulations tested in Example 2.

Example 4 Comparison of Two Independent Lots of a Single NX1843 Formulation.

NXl 843 lot numbers SMC-991-96 and SMC-1092-09 (see Table 1A) were used.

Male Sprague-Dawley rats weighing 207.16 to 219.27 grams were used for the study. The in-hfe phase of the study was conducted in Boulder Colorado in accordance with the guidehnes for animal welfare and care (NRC Pubhcation Guide for the Care and Use of Laboratory Animals, 1996). IACUC protocol number N98010. Animals were allowed free access to food and water before and during treatment.

Individual animals were weighed and dosed at 1 mg/kg body weight by intravenous bolus administration into the tail vein while under isoflurane anesthesia. Serial EDTA-blood samples (0.5 mL) were obtained at 10, 30 and 90 minutes and 4, 8, 24, 32, 48, 72 and 96 hours post-dosing (nominal times) while under isoflurane anesthesia. The EDTA-blood samples were immediately processed for plasma and stored at -20° C until analysis. The total concentration of GWl 843 in plasma was determined as in Example

3.

The pharmacokinetic parameters for total GWl 843 after intravenous administration of hposome encapsulated GWl 843 were assessed as described in Example 3. Comparison of treatment groups was performed by unpaired t-tests of the data. A p-value of <0.05 was considered significant except when multiple comparisons were performed in which case the Bonferroni correction was utihzed. Tests were performed using GraphPad istat version 1.0 (GraphPad Software).

Results The plasma concentrations for hposome encapsulated GWl 843 (NXl 843) lot SMC-1092-09 dose group are summarized in Table 8 while the corresponding plasma concentrations for the NXl 843 lot SMC-991-96 dose group are summarized in Table 9. The estimated values of several calculated pharmacokinetic parameters for NXl 843 lot SMC-1092-09 and NXl 843 lot SMC-991-96 are given in Table 10 and Table 11, respectively.

Estimates for the maximum achieved concentrations (Cmax) in the plasma of animals receiving NXl 843 lot SMC-1092-09 ranged from 16.9 to 23.1 μg/mL of total GW1843 (mean=19.1 μg/mL). Estimates for the Cmax in the plasma of animals receiving NXl 843 lot SMC-991-96 ranged from 15.0 to 18.4 μg/mL of total

GW1843 (mean=16.8 μg/mL). The observed differences in the mean Cmax values for each group were not significantly different (p=0.2161). The estimated (mean + SD) terminal half-hfe (Ehm.tl/2) obtained for lot SMC-1092-09 and lot SMC-991-96 were 12.2 ± 0.06 hr and 11.7 ± 0.96 hours, respectively. The observed differences in the half-lives obtained for the two lots were not significantly different (p=0.3386). Likewise, the differences observed for the mean of the Nss for lot SMC-1092-09 (70.8 mlJkg) and lot SMC- 1092-991-96 (65.8 mlJkg) were not significant (p=0.2784). Finally, the observed differences between the AUC(O-inf) of the two lots [276 ± 21.9 μg.hr/mL for SMC-1092-09 and 293 ± 53.8 μg.hr/mL for SMC-991-96 (ρ=0.5797)] or between the clearance of the two lots [3.65 ± 0.28 mIJhr.kg for SMC- 1092-09 and 3.50 + 0.59 mIJhr.kg for SMC-991-96 (p=0.6623)] were not significant.

Several pharmacokinetic parameters obtained for lot SMC-991-96 in this Example were significantly different from those obtained for this same lot in Example 3. Both Examples utihzed the same dose, route of administration and strain of rats (see Example 3). Two-tailed, unpaired t-tests were used to test the statistical significance of five different pharmacokinetic parameters. Because five comparisons were performed a Bonferroni correction was made such that a value of p<0.01 was necessary for significance. The differences observed in the means were statistically significant for all five parameters tested. Statistically significant differences were observed for plasma clearance (p=0.0024), volume of distribution at steady state (p=0.0027), plasma terminal half-hfe (p=0.0003), Cmax (p=0.0022) and AUC(O-inf) (p=0.0010). The AUC(O-inf) for this Example was 55% of the AUC(O-inf) achieved in

Example 3. Examination of the AUC over the first 24 hours [AUC(0-24)] shows that lot SMC-991-96 in this Example (206 ± 29.4 μg.hr/mL) was only 64% of the AUC(0- 24) achieved for the same lot in Example 3 (320 ± 27.5 μg.hr/mL). This data revealed that the majority of the difference in plasma exposure was observed in the first 24 hours. However, the AUC(0-24) was 61 % of the AUC(O-inf) in Example 3, while it was 70% in this study suggesting that the faster terminal phase seen in this study also played a role in reducing the overall plasma exposure.

No statistically significant pharmacokinetic differences were observed between lots SMC-1092-09 and SMC-991-96. Statistically significant pharmacokinetic differences were observed between the results in this Example and Example 3 for lot SMC-991-96.

Differences in animal weight between this Example and Example 3 hkely have contributed to the pharmacokinetic differences observed between studies for lot SMC-991-96.

Example 5

Comparison of Different Liposome Formulations and Determination of the

Effect of Animal Weight on Plasma Pharmacokinetics. Materials and Methods

NXl 843 lot numbers SMC-1092-09, AT-1084-97B, AT-1084-91B and AT- 1084-88B were used.

Male Sprague-Dawley rats weighing 207.78 to 228.76 grams were used to evaluate all lots, hi addition, large male Sprague-Dawley rats weighing 403.12 to 418.28 grams were used to evaluate lot AT-1084-91B in large rats. The in-hfe phase of the study was conducted in Boulder Colorado in accordance with the guidehnes for animal welfare and care (NRC Pubhcation Guide for the Care and Use of Laboratory Animals, 1996). IACUC protocol number N98010. Animals were allowed free access to food and water before and during treatment.

Individual animals were weighed and dosed at 1 mg kg body weight by intravenous bolus administration into the tail vein. Serial EDTA-blood samples (0.5 mL) were obtained at 10, 30 and 90 minutes and 4, 8, 24, 32, 48, 72 and 96 hours post-dosing. The EDTA-blood samples were immediately processed for plasma and stored at -20° C until analysis. Plasma samples were obtained under isofluorane anesthesia.

The total concentration of GWl 843 in plasma was determined as in Example 3.

The pharmacokinetic parameters for total GWl 843 after intravenous administration of GWl 843 or hposome encapsulated GWl 843 were assessed as described in Example 3.

Statistical testing was performed by a one way ANOVA for unpaired data. A p-value of <0.05 was considered significant. Tests were performed using GraphPad histat version 1.0 (GraphPad Software).

Results

Animals were assigned to one of five groups (n=4 in each group). Groups A-D were composed of animals with an average weight of 223 grams while Group E was composed of animals with an average weight of 409 grams. Animals in each group received a 1 mg/kg i.v. bolus dose of a hposome encapsulated GWl 8343 formulation. Group A was dosed with lot AT-1084-97B, a formulation containing a basic internal pH. Groups B, C and E each received the standard NXl 843 formulation. Group B received test article from lot SMC-1092-09 while groups C and E received the test article from lot AT-1084-91B. Group D animals were dosed with lot AT-1084-88B, a lot consisting of a high hpid to drag ratio. The total plasma GWl 843 concentrations for each animal in each dose group are shown in Tables 12-16. The estimated values of several calculated pharmacokinetic parameters determined by non-compartmental analysis for each animal in each dose group are shown in Tables

17-21. A one way ANOVA was performed on the clearance [Dose(μg/kg)/AUC(0- inf) (μg.hr/mL)] of all five groups. This test revealed significant differences between groups (p<0.0001). Seven post tests were performed (between groups A and B, A and C, B and C, B and D, B and E, C and D, and C and E) the results of which are discussed below.

Intra-Study Analysis of the Pharmacokinetic Parameters of Two Independent Lots of the Same NX1843 Formulation.

Two independent lots of the same standard hposome formulation of NXl 843 were compared in equivalent sized (-220 gram) rats. Group B animals received lot SMC-1092-09 while group C animals received lot AT-1084-91B. The plasma terminal half-hfe obtained for group B (10.6 ± 1.10 hr) was not obviously different from the terminal half-hfe obtained for group C (11.7 ± 0.535 hr). Although the AUC(O-inf) obtained for group B (253 ± 28.4 μg.hr/mL) appeared to be less than the AUC(O-inf) obtained for group C (347 ± 51.2 μg.hr/mL), post tests following the one way ANOVA analysis for clearance showed no statistically significant differences in clearance between group B and group C (p=0.0606).

Although this plasma clearance result may also be viewed as "marginally significant," a similar intra-study comparison of independent lots of the same hposome encapsulated formulation of GWl 843 (NXl 843) gave unequivocal results (Example 4). In this study, one group of male Sprague-Dawley rats received 1 mg/kg of lot SMC-1092-09 while the other group of male Sprague-Dawley rats received 1 mg/kg of lot SMC-991-96. This study did not show statistically significant differences between the two groups in any plasma pharmacokinetic parameter analyzed including plasma clearance (p=0.6623).

Table 22 summarizes the total GWl 843 plasma pharmacokinetic parameters obtained from two studies for three independent lots of the standard formulation of NXl 843 (Examples 4 and 5). All of this data has been determined from male Sprague-Dawley rats of equivalent weight following a 1 mg/kg i.v. bolus dose of test article. In light of the data as a whole, no inter-lot differences in total GWl 843 plasma pharmacokinetic parameters have been observed between different lots of the same hposome formulation. Inter-Study Analysis of the Pharmacokinetic Parameters Obtained from Two Studies with the Same Lot of the Standard Liposome Formulation of GW1843 (NX1843) in Rats of Equivalent Weight

hi this Example, rats (group B) received a 1 mg kg i.v. bolus dose of lot

SMC-1092-09. hi Example 4, a group of rats of similar weight also received a 1 mg kg i.v. bolus dose of lot SMC-1092-09. The total GWl 843 plasma pharmacokinetic parameters obtained for the rats that received this lot of test article in this Example and in Example 4 (study R990198-138E) are shown in Table 22. No obvious differences between the studies can be detected. The plasma terminal half- hfe obtained for group B in this Example (study R2000007-138E) (10.6 ± 1.10 hr) was not obviously different from the terminal half-hfe obtained for the SMC-1092-09 group in Example 4 (study R990198-138E) (12.2 ± 0.06 hr). Likewise, the plasma clearance obtained for group B in this Example (3.99 ± 0.417 mL/hr.kg) was not obviously different from the plasma clearance obtained for the SMC-1092-09 group in Example 4 (study R990198-138E) (3.65 ± 0.283 mL/hr.kg). High Internal pH and High Lipid to Drug Ratio Formulations.

The pharmacokinetic profiles of two alternative hposome GWl 843 formulations were examined in approximately 220-gram animals. Group A received a formulation containing a high internal pH while group D received a formulation containing an increased hpid to drag ratio. For comparison, groups B and C, also composed of -220-gram animals, received two independent lots of the standard hposome formulation of GWl 843 (NXl 843).

There were no obvious differences between the plasma pharmacokinetic parameters observed for the high internal pH group and the two groups that received the standard formulation. Of note, is that the terminal half-hfe for group A (9.83 ± 0.215 hr) was not obviously different from the terminal half-lives observed for group B (10.6 ± 1.10 hr) or group C (11.7 ± 0.535 hr). Likewise, the AUC(O-inf) obtained for group A (283 ± 23.7 μg.hr/mL) was in between the AUC(O-inf) obtained for group B (253 ± 28.4 μg.hr/mL) and Group C (347 ± 51.2 μg.hr/mL). Post tests following the one way ANONA analysis for clearance, showed no statistically significant differences in clearance between group A (3.56 ± 0.295 ιnL/hr.kg) and group B (3.50 ± 0.589 rrilJhr.kg) or between group A and group C (2.94 ± 0.489 πιIJhr.kg). There were obvious differences between the plasma pharmacokinetic parameters observed for the high hpid to drag ratio group (group D) and the two groups that received the standard formulation (groups B and C). Of note, is that the terminal half-hfe for group D (11.7 ± 1.88 hr) was not obviously different from the terminal half-lives observed for group B (10.6 ± 1.10 hr) or group C (11.7 ± 0.535 hr). However, the AUC(O-inf) obtained for group D (169 ± 28.8 μg.hr/mL) appeared to be smaller than the AUC(O-inf) obtained for group B (253 ± 28.4 μg.hr/mL) or for Group C (347 ± 51.2 μg.hr/mL). Post tests following the one way AΝONA analysis for clearance showed statistically significant differences in between group D and group B (p=0.0038) and between group D and group C (p=0.0005).

ΝX1843 Pharmacokinetics in Large Versus Small Rats.

Examination of previous pharmacokinetic studies (Example 2, 3, and Example 4) in male Sprague-Dawley rats revealed that, following a 1 mg/kg i.v. bolus dose of hposome encapsulated GWl 843 (NXl 843), total GWl 843 plasma clearance (mLVhr.kg) may vary with animal weight, h order to test this hypothesis, two groups of male Sprague-Dawley rats in this study received a 1 mg/kg i.v. bolus dose of the same lot of NXl 843 (Groups C and E). Animal weights differed between groups so that those in group C averaged 226 grams while those in group E averaged 409 grams. Examination of the resulting pharmacokinetic parameters revealed probable differences. For example, the plasma terminal half-hfe of group E animals was longer (14.0 ± 2.03 hr) than for group C animals (11.7 ± 0.535 hr). Likewise, the Cmax of group E animals was larger (25.2 ± 1.33 μg/mL) than for group C animals (20.4 ± 1.23 μg/mL). These differences are also reflected in differences in the AUC(O-inf) between groups C and E. Group E animals had a AUC(O-inf) of 549 ± 58.0 μg.hr/mL while group C animals had a AUC(O-inf) of 347 ± 51.2 μg.hr/mL. However, the one way ANONA analysis for clearance between groups C and E showed only a "marginally significant" result (p=0.0522). When combined, though, with results from previous Examples (study numbers R990164-138E and R990198- 138E) the differences between large and small animals become clear. Table 23 shows the combined results of the plasma pharmacokinetic parameters obtained from two independent lots of the same formulation of ΝX1843 that were studied in both large and small rats. The two experiments in large ammals had similar clearance values, 1.93 ± 0.207 mIJhr.kg and 1.84 ± 0.191 mIJhr.kg. However, in smaller animals, higher clearance values were obtained in the two independent experiments (3.50 ± 0.589 mIJhr.kg and 2.94 ± 0.489 mIJhr.kg). Thus from the combined data, it is clear that values for clearance differ when determined by a μg/kg basis. If the clearance is determined, however, using total dose (mlJhr) then the clearance values obtained are similar for large and small animals. Recalculation of the clearance values shown in Table 23 by the total dose method gives 0.73mIJhr and 0.65 mlJhr for the two studies composed of approximately 220 gram animals and gives 0.75 mlJhr and 0.74 mlJhr for the two studies composed of approximately 400 gram animals. hi equivalent sized animals, no statistically significant differences were observed between the plasma clearance (mIJhr.kg) of the hposome encapsulated GWl 843 formulation (lot SMC- 1092-09) obtained in the present Example and in Example 4. hi equivalent sized animals, no statistically significant differences in plasma clearance (mIJhr.kg) were observed between two independent lots (SMC-1092-09 and AT-1084-91B) of the same hposome encapsulation GW1843 formulation (NXl 843).

Differences in plasma clearance (mIJhr.kg) for the standard formulation are observed based on animal weight. This conclusion is based upon comparisons of lot AT-1084-91B in large and small animals in this example and of lot SMC-1092-09 in small animals in this example and Example 4 and of lot SMC-996-91 in small animals in Example 4 and large animals in Example 3. Thus, the hypothesis given in

Example 4 to explain the PK differences has been verified. Plasma clearance appears constant between large and small rats when calculated as [Total Dose (μg)/AUC(0-mf) (μg.hr/mL)] = mlJhr.

In equivalent sized animals, the high hpid to drug ratio formulation (lot AT- 1084-88B) was cleared more rapidly than was the standard formulation (lots SMC- 1092-09 and AT-1084-91B) or the high internal pH formulation (lot AT-1084-97B), but was still cleared from plasma significantly more slowly than free GWl 843 (Examples 2 and 3). hi equivalent sized animals, the high internal pH formulation (lot AT-1084- 97B) had a plasma clearance value that was similar to the standard formulation (lots SMC-1092-09 and AT-1084-91B). Thus, this formulation was also cleared from plasma significantly more slowly than free GWl 843 (Examples 2 and 3).

Example 6

Plasma Pharmacokinetics Following a Single Intravenous Bolus Administration.

The purpose of this example was to extend the analysis of alternative formulations of hposome encapsulated GWl 843. Here a formulation consisting of a 4:1 HSPC to cholesterol molar ratio was tested. Other formulations consisted of a 2:1 molar ratio. Cholesterol is known to stabihze the hposome structure so that it is expected that an increased HSPC to cholesterol ratio should increase plasma clearance.

Results

NXl 843 lot number AT-1105-32 (Table 1A) was used. Male Sprague-Dawley rats weighing 244.57 to 257.19 grams were used for the study. The in-life phase of the study was conducted in Boulder, Colorado in accordance with the guidehnes for animal welfare and care (NRC Pubhcation Guide for the Care and Use of Laboratory Animals, 1996). Animals were allowed free access to food and water before and during the study. Individual animals were weighed and dosed at 1 mg/kg body weight by intravenous bolus administration into the tail vein.

EDTA-blood samples (0.5 mL) were obtained at 10, 30 and 90 minutes and 4, 8, 24, 32, 48, and 72 hours post-dosing. Samples were taken while the animals were under anesthesia (isoflurane) and the EDTA-blood samples were immediately processed for plasma and plasma samples were stored at -20°C until analysis.

The total concentration of GWl 843 in plasma was determined as in Example 3.

The pharmacokinetic parameters for total GWl 843 after i.v administration of hposome encapsulated GWl 843 were assessed as described in Example 3. Comparison of treatment groups was performed by unpaired t-tests of data obtained in the same experiment. A p-value of <0.05 was considered significant. Tests were performed using GraphPad istat version 1.0 (GraphPad Software). Results

The total GWl 843 plasma concentrations for each animal are summarized in Table 24. The estimated values of several calculated pharmacokinetic parameters for the hposome encapsulated GWl 843 (NXl 843) 4:1 HSPC to cholesterol molar ratio formulation are given in Table 25.

Estimates for the maximum achieved concentrations (Cmax) for total GWl 843 in the plasma ranged from 14.4 μg/mL (rat #2) to 17.2 μg/mL (rat #3). The mean Cmax for all four animals was 15.8 μg/mL. The estimated (mean ± SD) terminal half-hfe (Ehm.tl/2) was 9.92 ± 1.98 hours well within the range observed for the standard hposome encapsulated GWl 843 formulation. The area under the total GW1843 plasma concentration versus time curve [AUC(O-inf)] was 213 ± 22.8 hr.μg/mL. This area under the curve is somewhat less than that observed for the standard hposome formulation, range 251 to 342 hr.μg/mL. This is reflected in the plasma clearance value obtained for the 4:1 HSPC to cholesterol formulation (4.74 + 0.472 mIJ(hr.kg)). The range of mean clearance values obtained for three different lots of the standard formulation in 4 experiments with nearly equivalent sized animals (Examples 4 and 5) was 3.50 to 3.99 mIJ(hr.kg). Previous studies have shown that plasma clearance, on a mIJ(hr.kg) basis, decreases with increasing animal weight (Example 5). The average weight of animals in this study was 250 grams while the comparative studies of the standard hposome encapsulated GWl 843 formulation were performed with rats that weighed on average 220 grams (range mean weights of animals for the four studies was 215 to 224 grams). Thus, the use of animals in this study with a weight of approximately 220 grams would have likely increased the observed differences.

The NXl 843 formulation consisting of a 4:1 hpid to cholesterol ratio (lot AT- 1105-32) was cleared from plasma shghtly faster than the standard hposome formulation. Clearance for lot AT-1105-32 was 4.74 ± 0.472 mIJ(hr.kg). The range of mean clearance values obtained in nearly equivalent sized animals for three different lots of the standard formulation in 4 experiments (Examples 4 and 5) was 3.50 to 3.99 mIJ(hr.kg). This formulation (lot AT-1105-32) was still cleared from plasma significantly more slowly than free GWl 843 (see Examples 2 and 3).

Example 7

Preclinical Studies on the TS Inhibitor GW1843U89 and the Liposomal Formulation NX 1843.

Methods Female Nu/Nu mice (18-24g , 10-14 weeks old) were obtained from Harlan

Sprague Dawley, and housed in microisolator filtration racks and maintained with filtered acidified water and sterile lab chow ad libitum. The human colon tumor xenograft model (HCT-8, thymidine kinase (TK)-/-) was obtained from Dr. Youcef M. Rustum (Roswell Park, Buffalo, New York), and established in-house as a useful model for evaluation of thymidylate synthase inhibitors. Animals were allowed to acclimate to their new environment for 1 week prior to tumor cell implantation. Tumors were established by injecting harvested tumor cells in a single subcutaneous site on the flank of the mice in the axillary region. The tumors were grown until approximately 200 +/- 50mm.3 in size. The animals were then sorted according to body weight, grouped four animals / cage, and tattooed on the tail for permanent identification. Groups consisting of 8 tumor-bearing mice each were administered weekly doses of experimental agents by IN bolus injection through the tail vein. Tumor volumes were determined with vernier cahper measurements taken at right angles using the formula, ( L x W²/ 2 ) and body weights, were collected twice weekly. Data was plotted as % change in body weight vs. time in days, and % tumor volume increase vs. days.

Methods of calculating anti-tumor activity from experimental results were as follows:

Inhibition and Regression Calculations Commonly Used For Assessing Experimental Data:

% T/C = 100 x l- ( T/ C )

T = ( mean ) time in days for treated group to reach cutoff size ( 2 grams ) C = ( mean ) time in days for control group to reach cutOff size ( 2 grams ) % T/C value less than 10% is indicative of significant activity; and %T/C value of < or = 20% is indicative of moderate activity.

% Tumor Growth Inhibition

%TGI = 100 ( W_c - W_t )/ W_c = 100 ( 1- W_t/ W_c ) W_c is the mean tumor weight of control group at time x W_t is mean tumor weight of treated group at time x If the starting tumor size between groups is great, the relative differences ( RW ) in tumor growth of the control and treated groups is used to correct for the initial differences.

RW = Wi / W₀, where Wj is the mean tumor weight at time x, and W₀ is the initial mean tumor weight.

% Regression = 100 ( W₀- Wi ) / W_{0 ;} where W₀ is the mean tumor weight for treated group at the initiation of treatment and Wi = the mean tumor weight for that group at time some time x after treatment. Many times the time x = 24-48 hr after the final dose of therapy.

Growth delay measures used to assess experimental results:

Tumor Cell Kill Calculations for sc growing tumors:

The log ₁₀ cell kill ( gross ) = [ T- C value in days / ( 3.32 ) ( T_d )

Where T-C = time difference in days between Treated and Control tumors to reach a defined end point; and Td is the Tumor Nolume Doubhng time in days from the best- fit straight line from a log-linear growth plot of the control tumors exponential growth ( 100-800 mg range ). The conversion of the T-C values to the net log ₁₀ tumor cell kill are provided by subtraction of the duration of the treatment period from the T-C value and then dividing by 3.32 X T_d.

HCT-8, TK-/- xenograft model The initial experiment, designated NMX-427, tested the effects of GW1843U89 at two different dose levels, 50 and lOOmg/kg/day x 17 days. The control group received vehicle alone. The experiment demonstrated little difference between the two dose groups, and both drag groups were significantly different from control with log cell kill values of 3.0 and 3.3 for the 50 and lOOmg/kg groups, respectively. There were two durable cures, one in each of the dose groups, which remained until termination of the experiment at day 57. The side-effect toxicity as measured by gross body weight loss was minimal in both drug-treated groups, and was greatest in the control group. This may reflect tumor induced cachexia, an effect induced by some actively growing tumors.

The second xenograft study compared the anti-tumor efficacy of hposomal formulated GW1843U89 (Table 1A; NA-1022-59A) dosed at 7.5mg/kg every-other day, to free drag dosed every day at 25 and 50mg/kg. The amount of hposomal drag allowed only 14 days of dosing (7 doses). The total amounts of free drug given were 350mg/kg and 700mg/kg while in the NXl 843 group total drag given was

52.5mg/kg. Table 26 summarizes the results which clearly demonstrate that the hposomal drug was more efficacious than the free drag, requiring less total drag administered on a less frequent schedule. The effects of the hposomal drug demonstrate superior efficacy to free drug, with 83% regression and log cell kill of 4.6, compared to the 25 and 50mg/kg free drug groups, where no tumor regression occurred, and these were log cell kill values of 1.5 and 3.5, respectively. Figure 2 shows the tumor growth curves, and demonstrates a dose response effect with free drug groups, and a more delayed tumor outgrowth with the NX 1843 group. The relative effect of the drags on body weight is shown in Figure 3. The body weight loss in all the drag groups was transient and reversible, never exceeding 10%.

A dose schedule study was performed with NXl 843 (Table 1A; SMC-991- 96), where HCT-8 tumor- bearing nude mice were dosed iv with NXl 843 at the following dose and schedule: 25mg/kg; quantity dehvered 1,8; 15mg/kg; QD(1,3,5) x 2; 7.5mg kg; QD(l-5) x 2. hi addition to these dose groups the free drug was dosed at lOOmg/kg on days 1-5, and repeated for a second week. Also included in this experiment were the following: 5-fluorourcil (SFU) dosed at lOOmg/kg on days 1 and 8; a hposomal formulation of a camptothecin analog (NX211) at 6mg/kg days 1 and 8; NX211 + 5FU dosed on days 1 and 8 at 6mg/kg and lOOmg/kg, respectively; NX211 at 6mg/kg days 1,8 + free GWl 843 at lOOmg/kg days 1-5 x 2; and NX211 + NXl 843 at 6mg/kg and 25mg/kg days 1,8. The Results are shown in Table 27. All three of the NXl 843 dose groups demonstrated equivalent efficacy with log cell kill (LCK) values ranging between 3.9-4.2, with 1/8 durable cures in each group. When NX 211 was combined with either NX 1843 or GW 1843, the overall tumor effects were similar, with LCK values of 3.4. There were, however, 2/8 durable cures generated with the NX 211 + NX 1843 combination. The dose groups of 5-FU alone, NX 211 alone, and GWl 843 alone all were less effective in inhibiting tumor growth, with LCK values of 1.5, 1.9, and 2.4, respectively. The least effective dose groups were the 5-FU alone, NX 211 alone, and the 5-FU + NX 211 combination. The free GW 1843 dose group was slightly better in hmiting tumor growth, but the greatest effect on tumor regression and overall inhibition of tumor growth were the NX 1843 dose groups, generating 5/32 durable cures. The body weight loss was transient and reversible, and never exceeded 20%. However, the NX 211 and 5-FU containing drag groups demonstrated the greatest amount of body weight loss.

Another experiment completed with NXl 843 was a dose response study where HCT-8 tumor-bearing mice were dosed iv. with NXl 843 on days 1 and 8 with the following dose: 25,20,15,10,5 mg/kg. The initial tumor shrinkage was similar in all dose groups except the lowest, where tumor growth was inhibited by 80%, compared to the other 4 groups where growth was inhibited from 92-99%. There was no appreciable effect on body weight in any of the dose groups, and 7/32 cures were generated. As can be seen in Figure 4, and Table 28, a dose dependent tumor response was evident.

Several variations in the hposomal formulation of NX 1843 have been produced and then tested in the HCT-8 xenograft model to determine if significant differences in efficacy could be determined. The variations included a range of HSPCCholesterol from 4:1 to 2:1, and a range in relative internal acidity from pH 5- 9. The results are displayed Table 29. This study demonstrated that no significant difference in antitumor efficacy was seen when comparing the different formulations of NX 1843 in the HCT-8 xenograft model. Pharmacokinetic differences between the different formulations tested were also minor and not significantly different. NX 1843 was further tested in the Molt4 leukemia model in SCID mice, hi this model morbidity and mortality are the measured end points. Tumor burden is estabhshed by implanting 1 x 10⁷ tumor cells iv., waiting 4 days, and then initiating treatment. The treatment groups consisted of NX 1843 at 25mg/kg +/- thymidine phosphorylase (Tpase). The Tpase treatment lowers mouse circulating Ihyrnidine levels to that of humans (50-100nM). The control group received D5W only. The results are shown in Figure 5, and demonstrate that NX 1843 increases survival irrespective of Tpase treatment.

The invention claimed herein has been described with respect to particular exemphfied embodiments. However, the foregoing description is not intended to hmit the invention to the exemphfied embodiments, and the skilled artisan should recognize that variations can be made within the scope and spirit of the invention as described in the foregoing specification. The invention includes the alternatives, modifications, and equivalents that may be included within the trae spirit and scope of the invention as defined by the appended claims.

Table 1 . liposomal formulations of GWl 843 prepared at different HSPC:Chol molar ratios, and different pH and concentration of dra solution at h dration.

Table IB. Additional GW1843 Li osomal Formulations

Table IC. Liposome Formulations Cont-tining Different Excipients

Preparation I.D. Excipient and concentration pH ofl Bnal product

NHC1202-027-4 9% Sucrose 6.5

NHC1202-027-1 lmM Phosphate and 9% Sucrose 7.5

NHC1202-027-2 5mM Phosphate and 9% Sucrose 7.7

NHC1202-027-3 lmM Citrate and 9% sucrose 7.1

NHC1202-089-2 lmM Succinate and 9% sucrose 6.6

Table ID. Median Diameter Stability (2-8°C) of Liposome Formulations Containing Different Excipients

Table 2. GWl 843 Plasma Concentrations in Rats Fohowing a Single 1 mg/kg Intravenous Bolus Dose in Rats.

^■P- us

Table 3. Pharmacokinetic Parameters by Noncompartmental Analysis for GWl 843 Fohowing a Single 1 mg/kg Intravenous Bolus Dose in Rats.

AUCinf AUClast Cl Cmax MRTirrf tl/2 Vss

(h x ng/mL) (h x ng/mL) (mL/h x kg) (ng/mL) (h) (h) (mL/kg)

Free Drug 263 219 3805 1281 0.5 0.5 1886.8 lipo H 7.0 266740 220640 3.75 15548 27.4 19.2 102.6 lipo pH 7.3 412307 339339 2.43 24124 27.3 18.7 66.2 lipo pH 7.4 412188 344089 2.43 18541 26.5 18.3 64.3 lipo pH 7.5 462920 387013 2.16 24790 26.1 17.9 56.3

Table 4. GWl 843 Plasma Concentrations fohowing a Single 1 mg/kg Intravenous Bolus Dose of Free GWl 843 in Male Sprague-Dawley Rats.

*Samρle actually taken at 0.267 hr.

**Data below estabhshed LLQ (0.1 μg/mL). Value obtained by extrapolation.

Table 5. Total GWl 843 Plasma Concentrations fohowing a Single 1 mg/kg Intravenous Bolus Dose of Liposome Encapsulate GWl 843 (NXl 843; SMC- 991-96) in Male Sprague-Dawley Rats.

Table 6. Plasma Pharmacokinetic Parameters for GWl 843 Fohowing a Single 1 mg/kg Intravenous Bolus Dose of Free GWl 843 in Male Sprague-Dawley Rats (Non-compartmental Analysis).

Table 7. Plasma Pharmacokinetic Parameters for GWl 843 Fohowing a Single lmg/kg Intravenous Bolus Dose of Liposome Encapsulated GWl 843 (NXl 843; SMC-991-96) in Male Sprague-Dawley Rats (Non-compartmental Analysis).

Table 8. Total GWl 843 Plasma Concentrations in Male Sprague-Dawley Rats Fohowing a 1 mg/kg IN. Bolus Administration of Liposome Encapsulated GWl 843 (ΝX1843) Lot SMC-1092-09.

BLOQ-Below hmit of quantification

Table 9. Total GWl 843 Plasma Concentrations in Male Sprague-Dawley Rats Fohowing a 1 mg/kg IN. Bolus Administration of Liposome Encapsulated GWl 843 (ΝX1843) Lot SMC-991-96.

*Sample taken at 0.517 minutes BLOQ-Below hmit of quantification.

Table 10. Plasma Pharmacokinetic Parameters for GWl 843 Fohowing a Single lmg/kg Intravenous Bolus Dose of Liposome Encapsulated GWl 843 (NXl 843), Lot SMC-1092-09, in Male Sprague-Dawley Rats (Non-compartmental Analysis).

Table 11. Plasma Pharmacokinetic Parameters for GWl 843 Fohowing a Single lmg/kg Intravenous Bolus Dose of Liposome Encapsulated GWl 843 (NXl 843), Lot SMC-991-96, in Male Sprague-Dawley Rats (Non-compartmental Analysis).

Table 12. Total GWl 843 Plasma Concentrations in Male Sprague-Dawley Rats (Group A) Fohowing a Single 1 mg/kg IN. Bolus Administration of a Liposome Encapsulated GWl 843 (ΝX1843) Formulation with a High Internal pH (Lot AT-1084-97B).

BLOQ-Below hmit of quantification

NS-No sample

*Sample taken at 1.583 hr.

**Sample taken at 1.550 hr.

⁺Mean and SD of three determined values.

Table 13. Total GWl 843 Plasma Concentrations in Male Sprague-Dawley Rats (Group B) Fohowing a Single 1 mg/kg IN. Bolus Administration of the Standard Formulation of Liposome Encapsulated GWl 843 (ΝX1843) (Lot SMC-1092-09).

BLOQ-Below hmit of quantification.

Table 14. Total GWl 843 Plasma Concentrations in Male Sprague-Dawley Rats (Group C) Fohowing a Single 1 mg/kg IN. Bolus Administration of the Standard Formulation of Liposome Encapsulated GWl 843 (ΝX1843) (Lot AT-1084-91B).

BLOQ-Below hmit of quantification *Sample taken at 0.500 hr. **Samρle taken at 0.583 hr.

Table 15. Total GWl 843 Plasma Concentrations in Male Sprague-Dawley Rats (Group D) Fohowing a Single 1 mg/kg IN. Bolus Administration of a Liposome Encapsulated GWl 843 (ΝX1843) Formulation with a High Lipid:Drug Ratio (Lot AT-1084-88B).

NS-No Sample

*Samρle taken at 1.533 hr.

Table 16. Total GWl 843 Plasma Concentrations in Large Male Sprague- Dawley Rats (Group E) Fohowing a Single 1 mg/kg IN. Bolus Admimstration of the Formulation of Uposome Encapsulated GWl 843 (ΝX1843) (Lot AT- 1084-9 IB).

ND-No Data

*Sample taken at 1.533 hr.

^""Mean and SD of the two data points determined.

Table 17. Plasma Pharmacokinetic Parameters (Non-compartmental Analysis) for Total GWl 843 Fohowing a Single lmg/kg IN. Bolus Dose of a Liposome Encapsulated GWl 843 (ΝX1843) Formulation with a High Internal pH (Lot AT- 1084-97B) in Male Sprague-Dawley Rats (Group A).

Table 18. Plasma Pharmacokinetic Parameters (Non-compartmental Analysis) for Total GWl 843 Fohowing a Single lmg/kg IN. Bolus Dose of the Standard Liposome Encapsulated GWl 843 (ΝX1843), Formulation (Lot SMC-1092-09) in Male Sprague-Dawley Rats (Group B).

Table 19. Plasma Pharmacokinetic Parameters (Non-compartmental Analysis) for Total GWl 843 Fohowing a Single lmg/kg IN. Bolus Dose of the Standard Liposome Encapsulated GWl 843 (ΝX1843) Formulation (Lot AT-1084-9 IB) in Male Sprague- Dawley Rats (Group C).

Table 20. Plasma Pharmacokinetic Parameters (Non-compartmental Analysis) for Total GWl 843 Following a Single lmg/kg IN. Bolus Dose of a Liposome Encapsulated GWl 843 (ΝX1843) Formulation with a High Lipid:Drug Ratio (Lot AT-1084-88B) in Male Sprague-Dawley Rats (Group D).

Table 21. Plasma Pharmacokinetic Parameters (Non-compartmental Analysis) for Total GWl 843 Fohowing a Single lmg/kg IN. Bolus Dose of the Standard Liposome Encapsulated GW1843 (ΝX1843) Formulation (Lot AT-1084-91B) in 0.4 kg Male Sprague-Dawley Rats (Group E).

Table 22. Summary Table of the Total GWl 843 Plasma Pharmacokinetic Parameters Obtained Fohowing a Single lmg/kg Intravenous Bolus Dose of the Standard Liposome Encapsulated GWl 843 (NXl 843) Formulation in 220 gram Male Sprague-Dawley Rats (Non-compartmental Analysis).

Table 23. Summary Table of the Total GWl 843 Plasma Pharmacokinetic Parameters Obtained Fohowing a Single lmg/kg Intravenous Bolus Dose of the Standard Liposome Encapsulated GWl 843 (NXl 843) Formulation in small (220 gram) versus Large (400g) Male Sprague-Dawley Rats (Non-compartmental Analysis).

Table 24. Total GWl 843 Plasma Concentrations Fohowing a Single 1 mg/kg Intravenous Bolus Dose of Liposome Encapsulated GWl 843 (4:1 HSPC to Cholesterol Molar Ratio) in Male Sprague-Dawley Rats.

BLOQ-Below hmit of quantification *Sample taken at 0.517 hr. ⁺Sample taken at 24.23 hr.

Table 25. Total GWl 843 Plasma Pharmacokinetic Parameters, Obtained by Noncompartmental Analysis, Fohowing a Single 1 mg/kg Intravenous Bolus Dose of Liposome Encapsulated GWl 843 (4:1 HSPC to Cholesterol Molar Ratio) in Male Sprague-Dawley Rats.

Table 26. Summary of results comparing NX 1843 to free drug

Table 27. Summary of NXl 843 dose-schedule comparison tumor response to combinations with 5-FU, NX211 and GWl 843.

Table 28. Summary of Dose Response Experiment with NX 1843.

% TGI and Regression were determined on day 26, cures were determined at day 60.

Table 29. Antitumor Efficacy Results, Comparison of NX 1843 Formulations Dosed at lOmg/kg, QD 1,8 in the HCT-8 Xenograft model.

Rank analysis of variance demonstrated no significant differences between lots, p 0.2985.

Claims (88)

We claim:

1. A hposome comprising at least one phosphatidylchohne, a

cholesterol, and a benzoquinazohne thymidylate synthase inhibitor.

2. The hposome of claim 1 wherein said phosphatidylchohne is

selected from the group consisting of distearoylphosphatidylchohne,

hydrogenated soy phosphatidylchohne, soy phosphatidylchohne, egg

phosphatidylchohne, hydrogenated egg phosphatidylchohne,

dipalmitoylphosphatidylcholine, dioleoylphosphatidylchohne,

dielaidoylphosphatidylchohne, and dimyristoylphosphatidylchohne.

3. The hposome of claim 2 wherein said phosphatidylchohne is

hydrogenated soy phosphatidylchohne.

4. The hposome of claim 2 wherein said phosphatidylchohne is soy

phosphatidylchohne.

5. The hposome of claim 2 wherein said phosphatidylchohne is

dioleoylphosphatidylchohne.

6. The hposome of claim 2 wherein said phosphatidylchohne is

dielaidoylphosphatidylchohne.

7. The hposome of claim 2 wherein said hposome further comprises

phosphatidylglycerol.

8. The hposome of claim 3 wherein said benzoquinazohne

thymidylate synthase inhibitor is GWl 843.

9. The hposome of claim 4 wherein said benzoquinazohne

thymidylate synthase inhibitor is GWl 843.

10. The hposome of claim 5 wherein said benzoquinazohne

thymidylate synthase inhibitor is GWl 843.

11. The hposome of claim 6 wherein said benzoquinazohne thymidylate synthase inhibitor is GWl 843.

12. The hposome of claim 7 wherein said benzoquinazohne

thymidylate synthase inhibitor is GWl 843.

13. The hposome of claim 12 wherein said hydrogenated soy phosphatidylchohne, cholesterol and phosphatidylglycerol are in a molar ratio of

about 2:1:0.1.

14. The hposome of claim 8 wherein the hydrogenated soy phosphatidylchohne to cholesterol molar ratio is from about 5:1 to 2:1.5.

15. The hposome of claim 14 wherein said molar ratio is about 2: 1.

16. The hposome of claim 14 wherein said molar ratio is about 4: 1.

17. The hposome of claim 15 wherein said hposome is unilamellar and less than 100 nm.

18. The hposome of claim 17 wherein said hydrogenated soy phosphatidylchohne to GWl 843 molar ratio is from about 5:1 to 75:1.

19. The hposome of claim 9 wherein said molar ratio is about 2: 1.

20. The hposome of claim 10 wherein said molar ratio is about 2: 1.

21. The hposome of claim 11 wherein said molar ratio is about 2: 1.

22. The hposome of claim 17 wherein said hydrogenated soy phosphatidylchohne to GWl 843 molar ratio is from about 8:1 to 20:1.

23. A hposome comprising a benzoquinazohne thymidylate synthase

inhibitor (BTSI) encapsulated in a hposome, wherein said hposome is comprised of hydrogenated soy phosphatidylchohne (HSPC) and cholesterol

and wherein HSPCxholesterol are in a molar ratio of about 2:1, and wherein the

HSPC:BTSI molar ratio is from 8:1 to 20:1, and wherein said hposome is

unilamehar having a size of less than 100 nm.

24. The hposome of claim 23 wherein said BTSI is GWl 843.

25. The composition of claim 1 produced by the process comprising:

a) forming a hpid film or powder comprised of phosphatidylchohne

and cholesterol;

b) hydrating said hpid film or powder with an aqueous solution

containing a benzoquinazohne thymidylate synthase inhibitor (BTSI);

c) applying energy whereby hposomes that are unilamellar and less

than 100 nm are obtained;

d) cross-filtering against an aqueous solution to remove

unencapsulated BTSI, whereby hposomes containing a BTSI are obtained.

26. The composition of claim 25 wherein said phosphatidylchohne is

selected from the group consisting of distearoylphosphatidylchohne,

hydrogenated soy phosphatidylchohne, soy phosphatidylchohne, egg

phosphatidylchohne, hydrogenated egg phosphatidylchohne,

dipalmitoylphosphatidylchohne, dioleoylphosphatidylchohne,

dielaidoylphosphatidylchohne, and dimyristoylphosphatidylchohne.

27. The composition of claim 26 wherein said phosphatidylchohne is

hydrogenated soy phosphatidylchohne.

28. The composition of claim 26 wherein said phosphatidylchohne is

soy phosphatidylchohne.

29. The composition of claim 26 wherein said phosphatidylchohne is dioleoylphosphatidylchohne.

30. The composition of claim 26 wherein said phosphatidylchohne is dielaidoylphosphatidylchohne.

31. The composition of claim 26 wherein said hposome further comprises phosphatidylglycerol.

32. The composition of claim 25 wherein said energy is apphed by a homogenizer.

33. The composition of claim 27 wherein said BTSI is GW1843.

34. The composition of claim 28 wherein said BTSI is GWl 843.

35. The composition of claim 29 wherein said BTSI is GWl 843.

36. The composition of claim 30 wherein said BTSI is GWl 843.

37. The composition of claim 31 wherein said BTSI is GWl 843.

38. The composition of claim 27 wherein the hydrogenated soy phosphatidylchohne to cholesterol molar ratio is from about 5: 1 to 2: 1.5.

39. The composition of claim 38 wherein said molar ratio is about 2:1.

40. The composition of claim 38 wherein said molar ratio is about 4:1.

41. The composition of claim 39 wherein said hposome is unilamellar and less than 100 nm.

42. The composition of claim 41 wherein said hydrogenated soy phosphatidylchohne to GWl 843 molar ratio is from about 5:1 to 75:1.

43. The composition of claim 42 wherein said hydrogenated soy

phosphatidylchohne to GWl 843 molar ratio is from about 8:1 to 20:1.

44. The composition of claim 25 wherein said BTSI is GWl 843 and

wherein said phosphatidylchohne is hydrogenated soy phosphatidylchohne

(HSPC), and wherein said HSPCxholesterol are in a molar ratio of about 2: 1 ,

and wherein the HSPC:BTSI molar ratio is from 8:1 to 20:1.

45. A process for making hposomes comprising a benzoquinazohne

thymidylate synthase inhibitor (BTSI), said method comprising:

a) forming a hpid film or powder comprised of phosphatidylchohne

and cholesterol;

b) hydrating said hpid film or powder with an aqueous solution

containing BTSI;

c) applying energy whereby hposomes that are unilamehar and less

than 100 nm are obtained;

d) cross-filtering against an aqueous solution to remove

unencapsulated BTSI, whereby hposomes containing BTSI are obtained.

46. The method of claim 45 wherein said phosphatidylchohne is

selected from the group consisting of distearoylphosphatidylchohne,

hydrogenated soy phosphatidylchohne, soy phosphatidylchohne, egg

phosphatidylchohne, hydrogenated egg phosphatidylchohne,

dipahnitoylphosphatidylchohne, dioleoylphosphatidylchohne,

dielaidoylphosphatidylchohne, and dimyristoylphosphatidylchohne.

47. The method of claim 46 wherein said phosphatidylchohne is

hydrogenated soy phosphatidylchohne.

48. The method of claim 46 wherein said phosphatidylchohne is soy phosphatidylchohne.

49. The method of claim 46 wherein said phosphatidylchohne is dioleoylphosphatidylchohne.

50. The method of claim 46 wherein said phosphatidylchohne is dielaidoylphosphatidylchohne.

51. The method of claim 46 wherein said hposome further comprises phosphatidylglycerol.

52. The method of claim 45 wherein said energy is apphed by a homogenizer.

53. The method of claim 47 wherein said BTSI is GWl 843.

54. The method of claim 48 wherein said BTSI is GWl 843.

55. The method of claim 49 wherein said BTSI is GWl 843.

56. The method of claim 50 wherein said BTSI is GWl 843.

57. The method of claim 51 wherein said BTSI is GWl 843.

58. The method of claim 47 wherein the hydrogenated soy phosphatidylchohne to cholesterol molar ratio is from about 5:1 to 2:1.5.

59. The method of claim 58 wherein said molar ratio is about 2: 1.

60. The method of claim 58 wherein said molar ratio is about 4: 1.

61. The method of claim 59 wherein said hposome is unilamehar and less than 100 nm.

62. The method of claim 61 wherein said hydrogenated soy phosphatidylchohne to GW1843 molar ratio is from about 5:1 to 75:1.

63. The method of claim 62 wherein said hydrogenated soy

phosphatidylchohne to GWl 843 molar ratio is from about 8:1 to 20:1.

64. The method of claim 45 wherein said BTSI is GWl 843 and

wherein said phosphatidylchohne is hydrogenated soy phosphatidylchohne

(HSPC), and wherein said HSPCxholesterol are in a molar ratio of about 2: 1 ,

and wherein the HSPCBTSI molar ratio is from 8: 1 to 20: 1.

65. A method of inhibiting the growth of a tumor comprising the

administration of a therapeutic or effective amount of the composition of claim

1 to a tumor.

66. The method of claim 65 wherein said tumor is drug resistant or

drug sensitive.

67. The method of claim 65 wherein said tumor is from a cancer

selected from the group consisting of ovarian, lung, colorectal, breast, head and

neck, prostate, uteran, ghoblastoma, and sarcoma.

68. The method of claim 67 wherein said phosphatidylchohne is

selected from the group consisting of distearoylphosphatidylchohne,

hydrogenated soy phosphatidylchohne, soy phosphatidylchohne, egg

phosphatidylchohne, hydrogenated egg phosphatidylchohne,

dipalmitoylphosphatidylchohne, dioleoylphosphatidylchohne,

dielaidoylphosphatidylchohne, and dimyristoylphosphatidylchohne.

69. The method of claim 68 wherein said phosphatidylchohne is

hydrogenated soy phosphatidylchohne.

70. The method of claim 68 wherein said phosphatidylchohne is soy

phosphatidylchohne.

71. The method of claim 68 wherein said phosphatidylchohne is dioleoylphosphatidylchohne.

72. The method of claim 68 wherein said phosphatidylchohne is dielaidoylphosphatidylchohne.

73. The method of claim 68 wherein said hposome further comprises phosphatidylglycerol.

74. The method of claim 69 wherein said benzoquinazohne thymidylate synthase inhibitor is GWl 843.

75. The method of claim 70 wherein said benzoquinazohne Ihyrnidylate synthase inhibitor is GWl 843.

76. The method of claim 71 wherein said benzoquinazohne thymidylate synthase inhibitor is GWl 843.

77. The method of claim 72 wherein said benzoquinazohne thymidylate synthase inhibitor is GWl 843.

78. The method of claim 73 wherein said benzoquinazohne thymidylate synthase inhibitor is GWl 843.

79. The method of claim 78 wherein said hydrogenated soy phosphatidylchohne, cholesterol and phosphatidylglycerol are in a molar ratio of about 2:1:0.1.

80. The method of claim 74 wherein the hydrogenated soy phosphatidylchohne to cholesterol molar ratio is from about 5:1 to 2:1.5.

81. The method of claim 80 wherein said molar ratio is about 2:1.

82. The method of claim 80 wherein said molar ratio is about 4: 1.

83. The method of claim 81 wherein said hposome is unilamehar and

less than 100 nm.

84. The method of claim 83 wherein said hydrogenated soy phosphatidylchohne to GWl 843 molar ratio is from about 5:1 to 75:1.

85. The method of claim 75 wherein said molar ratio is about 2:1.

86. The method of claim 76 wherein said molar ratio is about 2: 1.

87. The method of claim 77 wherein said molar ratio is about 2: 1.

88. The method of claim 83 wherein said hydrogenated soy phosphatidylchohne to GWl 843 molar ratio is from about 8:1 to 20:1.